clarithromycin has been researched along with midazolam in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 14 (42.42) | 24.3611 |
| 2020's | 4 (12.12) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Laufen, H; Yeates, RA; Zimmermann, T | 1 |
| Laufen, H; Schumacher, T; Yeates, RA; Zimmermann, T | 1 |
| Gorski, JC; Haehner-Daniels, BD; Hall, SD; Hamman, MA; Jones, DR; O'Mara, EM | 1 |
| Cantrell, VE; Eckstein, J; Hall, SD; Hamman, MA; Jones, DR; Ring, BJ; Ruterbories, K; Williams, JA; Wrighton, SA | 1 |
| Ito, K; Itoh, T; Kanamitsu, S; Ogihara, K | 1 |
| Arefayene, M; Chalasani, N; Gorski, JC; Hall, SD; Hamman, MA; Kolwankar, D; Liangpunsakul, S; Pinto, AG; Skaar, T; Wang, YH | 1 |
| Breen, P; Carrier, DJ; Cheboyina, S; Gentry, WB; Gurley, B; Hubbard, MA; Thaden, J; Tong, Y; Williams, DK | 1 |
| Gentry, WB; Gurley, BJ; Hartsfield, F; Hubbard, MA; Swain, A; Thaden, J; Tong, Y; Williams, DK | 1 |
| Gorski, JC; Haehner, BD; Hall, SD; Lin, Z; Quinney, SK; Rhoades, MB | 1 |
| Cheng, ZN; Hu, ZY; Li, XM; Luo, X | 1 |
| Gorski, JC; Hall, SD; Li, L; Lucksiri, A; Quinney, SK; Zhang, X | 1 |
| Alder, J; Brown, HS; Houston, JB; Wilby, AJ | 1 |
| Baba, T; Kadono, K; Kanazu, T; Sato, N; Takeda, Y; Touchi, A; Yamaguchi, Y | 1 |
| Chalasani, N; Gorski, JC; Hall, SD; Hamman, MA; Malireddy, SR; Quinney, SK; Vuppalanchi, R | 1 |
| Becka, M; Kubitza, D; Mueck, W | 1 |
| Burhenne, J; Haefeli, WE; Hellwig, R; Markert, C; Mikus, G; Riedel, KD; Schweizer, Y; Weiss, J; Wirsching, T | 1 |
| Burhenne, J; Haefeli, WE; Hellwig, R; Hoffmann, MM; Markert, C; Mikus, G; Weiss, J | 1 |
| Britz, H; Eissing, T; Frechen, S; Hanke, N; Lehr, T; Moj, D; Wendl, T | 1 |
| Cahn, AP; Georgiou, A; Harrell, AW; Hessel, EM; Marotti, M; Patel, A; Riddell, K; Taskar, KS; Taylor, M; Tracey, H; Wilson, R | 1 |
| Battegay, M; Courlet, P; Decosterd, LA; Kinvig, H; Marzolini, C; Penny, MA; Siccardi, M; Stader, F | 1 |
| Cho, JY; Jang, IJ; Ji, SC; Kim, AH; Lee, J; Lee, S; Lee, Y; Yoon, S; Yoon, SH; Yu, KS | 1 |
| Abraham, TL; Bedwell, DW; Hall, SD; Hansen, K; Rougée, LRA | 1 |
2 review(s) available for clarithromycin and midazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly.
Topics: Adult; Aged; Aged, 80 and over; Aging; Clarithromycin; Cohort Studies; Comorbidity; Computer Simulation; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Models, Biological; Polypharmacy; Prospective Studies; Rifampin; Young Adult | 2021 |
13 trial(s) available for clarithromycin and midazolam
| Article | Year |
|---|---|
Interaction between midazolam and clarithromycin: comparison with azithromycin.
Topics: Adult; Analysis of Variance; Anti-Anxiety Agents; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Female; Humans; Male; Midazolam; Middle Aged; Sleep | 1996 |
Pharmacokinetic and pharmacodynamic interaction study between midazolam and the macrolide antibiotics, erythromycin, clarithromycin, and the azalide azithromycin.
Topics: Anti-Anxiety Agents; Anti-Bacterial Agents; Area Under Curve; Azithromycin; Clarithromycin; Cross-Over Studies; Drug Interactions; Erythromycin; Female; Humans; Male; Midazolam | 1997 |
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
Topics: Administration, Oral; Adult; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gene Expression; Genotype; Humans; Intestinal Mucosa; Intestines; Male; Midazolam; Oxidoreductases, N-Demethylating; Time Factors | 2005 |
Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.
Topics: Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Area Under Curve; Cimicifuga; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dietary Supplements; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Female; Humans; Hypnotics and Sedatives; Male; Midazolam; Phenotype; Rifampin; Sex Characteristics; Silybum marianum | 2006 |
Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo.
Topics: Adult; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dietary Supplements; Enzyme Induction; Enzyme Inhibitors; Female; Herb-Drug Interactions; Humans; Hydrastis; Kava; Male; Midazolam; Models, Biological; Phenotype; Plant Preparations; Rifampin; Risk Assessment; Substrate Specificity | 2008 |
Interaction between midazolam and clarithromycin in the elderly.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anti-Anxiety Agents; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Injections, Intravenous; Intestines; Liver; Male; Midazolam; Regression Analysis | 2008 |
Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.
Topics: Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Humans; Hydrocortisone; Male; Midazolam; Young Adult | 2009 |
Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.
Topics: Administration, Oral; Adult; Analysis of Variance; Biopsy; Biotransformation; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Duodenum; Enzyme Inhibitors; Female; Genotype; Humans; Hydroxylation; Liver; Male; Midazolam; Middle Aged; Phenotype; Substrate Specificity; Young Adult | 2013 |
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Topics: Adolescent; Adult; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Metabolic Clearance Rate; Midazolam; Middle Aged; Morpholines; Rivaroxaban; Substrate Specificity; Thiophenes; Young Adult | 2013 |
Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.
Topics: Adult; Anti-Anxiety Agents; Bosentan; Clarithromycin; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Endothelin Receptor Antagonists; Female; Genotype; Healthy Volunteers; Humans; Liver-Specific Organic Anion Transporter 1; Male; Midazolam; Organic Anion Transporters; Sulfonamides | 2014 |
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.
Topics: Administration, Oral; Adult; Area Under Curve; Clarithromycin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Female; Gene Frequency; Humans; Liver-Specific Organic Anion Transporter 1; Male; Metabolic Clearance Rate; Midazolam; Nontherapeutic Human Experimentation; Organic Anion Transporters; Phenylpropionates; Polymorphism, Genetic; Pyridazines | 2013 |
Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Area Under Curve; Clarithromycin; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Healthy Volunteers; Humans; Indazoles; Indoles; Itraconazole; Male; Microsomes, Liver; Midazolam; Middle Aged; Models, Biological; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Prospective Studies; Retrospective Studies; Young Adult | 2020 |
Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects.
Topics: Administration, Intravenous; Administration, Oral; Adult; Biomarkers; Citrus paradisi; Clarithromycin; Cytochrome P-450 CYP3A; Food-Drug Interactions; Healthy Volunteers; Humans; Intestinal Mucosa; Liver; Male; Metabolic Clearance Rate; Midazolam | 2021 |
18 other study(ies) available for clarithromycin and midazolam
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Topics: Adult; Anti-Anxiety Agents; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Biological Availability; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Humans; Intestines; Liver; Male; Midazolam; Oxidoreductases, N-Demethylating; Reference Values; Sex Characteristics | 1998 |
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Topics: Alprazolam; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clarithromycin; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Cytochromes b5; Diltiazem; Estradiol; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Midazolam; Nifedipine; Tamoxifen; Testosterone; Triazolam | 2002 |
Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes.
Topics: Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Azithromycin; Clarithromycin; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Hydroxylation; Macrolides; Microsomes, Liver; Midazolam; Models, Biological; Oxidoreductases, N-Demethylating; Time Factors | 2003 |
Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
Topics: Anesthetics; Anti-Bacterial Agents; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Humans; Intestinal Mucosa; Liver; Male; Metabolic Clearance Rate; Midazolam; Models, Biological; Organ Specificity | 2010 |
Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.
Topics: Animals; Cell Separation; Clarithromycin; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Enoxacin; Enzyme Inhibitors; Hepatocytes; Male; Microsomes, Liver; Midazolam; Nelfinavir; Rats; Rats, Sprague-Dawley; Saquinavir; Theophylline | 2010 |
Investigation of drug-drug interaction via mechanism-based inhibition of cytochrome P450 3A by macrolides in dexamethasone-treated female rats.
Topics: Animals; Area Under Curve; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Interactions; Erythromycin; Female; Humans; Male; Microsomes, Liver; Midazolam; Models, Biological; Rats; Sex Factors; Species Specificity | 2012 |
PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Topics: Alfentanil; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Itraconazole; Midazolam; Models, Biological; Rifampin | 2018 |
Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4.
Topics: Carbamazepine; Clarithromycin; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Microsomes, Liver; Midazolam; Troleandomycin | 2023 |